3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Gynecologic
1
Gastrointestinal
1
Breast
1
Conditions
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Recurrence
1
Ovarian Neoplasms
1
Neoplasm Metastasis
1
Gastrointestinal Stromal Tumors
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Interventions
Paclitaxel
96
Carboplatin
81
Bevacizumab
62
Gemcitabine
36
liposomal doxorubicin
32
pembrolizumab
30
Topotecan
26
olaparib
23
Taxes
23
niraparib
17
Immunoglobulin G
17
Disulfides
17
Docetaxel
16
Cyclophosphamide
16
Cisplatin
14
Nivolumab
11
rucaparib
10
durvalumab
10
Doxorubicin
9
Albumin-Bound Paclitaxel
8
sargramostim
7
pazopanib
7
fludarabine phosphate
7
fludarabine
7
avelumab
7
Magnetic Resonance Spectroscopy
7
Ifosfamide
7
epacadostat
6
Trabectedin
6
Sorafenib
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Ovarian Neoplasms
×
tinostamustine
×
Clear all
NCT03345485
2024-10-21
EDO-S101
Mundipharma Research Limited
Phase 1/2
Completed
71 enrolled
39 charts